Xenon Pharmaceuticals (XENE) Retained Earnings (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Retained Earnings data on file, last reported at -$1.3 billion in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.3 billion, down 161105.98% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 161105.98% YoY), and the FY2025 annual result was -$1.2 billion, down 77156.82% from the prior year.
• Retained Earnings retreated to -$1.3 billion in Q1 2026 per XENE's latest filing, from -$1.2 billion in the prior quarter.
• Over five years, Retained Earnings peaked at -$836000.0 in Q1 2025 and troughed at -$1.3 billion in Q1 2026.
• A 5-year average of -$612.6 million and a median of -$620.4 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings jumped 99.88% in 2025, then tumbled 161105.98% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$482.7 million in 2022, then sank by 37.78% to -$665.1 million in 2023, then surged by 99.76% to -$1.6 million in 2024, then sank by 77156.82% to -$1.2 billion in 2025, then dropped by 8.21% to -$1.3 billion in 2026.
• Business Quant data shows XENE's Retained Earnings at -$1.3 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.1 billion in Q3 2025.